glp 1 drug makers Market Overview: GLP-1 Agonists and the Obesity Market | Blog India pharma companies develop versions
Description
This means that a large share of users stop using GLP-1 drugs
however, based on thyroid C-cell hyperplasia, adenomas, and medullary thyroid carcinomas observed in studies of these agents in mice (40), all of the GLP-1 receptor agonists except exenatide BID and lixisenatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 (1418)
doi: 10.2337/diacare.27.11.2628 53 ApovianCMBergenstalRMCuddihyRMQuYLenoxSLewisMSet al
Podbregar, M
Diabetes 2018;67(Suppl 1)
